Internal medicine
Service
Hospital Universitario San Juan de Alicante
San Juan de Alicante, EspañaPublications in collaboration with researchers from Hospital Universitario San Juan de Alicante (12)
2024
2022
-
Dolutegravir plus rilpivirine: benefits beyond viral suppression: DORIPEX retrospective study
Medicine (United States), Vol. 101, Núm. 24, pp. E29252
2021
-
Demographic, clinical, and functional determinants of antithrombotic treatment in patients with nonvalvular atrial fibrillation
BMC Cardiovascular Disorders, Vol. 21, Núm. 1
-
Estimation of Admission D-dimer Cut-off Value to Predict Venous Thrombotic Events in Hospitalized COVID-19 Patients: Analysis of the SEMI-COVID-19 Registry
Journal of General Internal Medicine, Vol. 36, Núm. 11, pp. 3478-3486
-
Evolution of the use of corticosteroids for the treatment of hospitalised COVID-19 patients in Spain between March and November 2020: SEMI-COVID national registry
Journal of Clinical Medicine, Vol. 10, Núm. 19
-
Healthcare workers hospitalized due to COVID-19 have no higher risk of death than general population. Data from the Spanish SEMI-COVID-19 Registry
PLoS ONE, Vol. 16, Núm. 2 February
-
Use of antihyperglycaemic therapy with cardiovascular benefit in patients with type 2 diabetes who require hospitalisation: A cross-sectional study
Revista Clinica Espanola, Vol. 221, Núm. 9, pp. 517-528
2020
-
Virological outcome among HIV infected patients transferred from pediatric care to adult units in Madrid, Spain (1997–2017)
Scientific Reports, Vol. 10, Núm. 1
2019
-
Diverse large HIV-1 non-subtype B clusters are spreading among men who have sex with men in Spain
Frontiers in Microbiology, Vol. 10, Núm. APR
2015
-
Nationwide study on the use of intravascular catheters in internal medicine departments
Journal of Hospital Infection, Vol. 90, Núm. 2, pp. 135-141
-
Outcome of neuropsychiatric symptoms related to an antiretroviral drug following its substitution by nevirapine: The RELAX study
HIV Medicine, Vol. 16, Núm. 10, pp. 628-634
2008
-
Didanosine, lamivudine, and efavirenz versus zidovudine, lamivudine, and efavirenz for the initial treatment of hiv type 1 infection: Final analysis (48 weeks) of a prospective, randomized, noninferiority clinical trial, GESIDA 3903
Clinical Infectious Diseases, Vol. 47, Núm. 8, pp. 1083-1092